{
    "nctId": "NCT00036868",
    "briefTitle": "Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer",
    "officialTitle": "A Randomized Phase II Study Of CMF Alone And In Combination With Anti c-erbB2 Antibody (Herceptin) In Women With c-erbB2 Positive Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 90,
    "primaryOutcomeMeasure": "Clinical heart failure rate measured by New York Heart Association classification, LVEF, and ECG",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed metastatic breast cancer c-erbB2 positive (3+ overexpression by the HercepTest\u2122 method) in the primary tumor or metastatic site\n* At least 1 unidimensionally measurable target lesion\n\n  * At least 20 mm by conventional techniques OR\n  * At least 10 mm by spiral CT scan\n  * Lesions that have been irradiated in the preceding 3 months cannot be used as target lesions unless they have appeared or clearly progressed since prior irradiation\n  * No bone lesions as the only target lesions\n* No contralateral breast cancer that is c-erbB2-positive or c-erbB2-negative/unknown, with status determined on a metastatic site\n* No CNS metastases\n\n  * CT scan of brain and CSF cytology are required if neurologic symptoms are present\n* Hormone receptor status:\n\n  * Any estrogen or progesterone receptor status\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 18 and over\n\nSex:\n\n* Female\n\nMenopausal status:\n\n* Any status\n\nPerformance status:\n\n* ECOG 0-2\n\nLife expectancy:\n\n* Not specified\n\nHematopoietic:\n\n* Neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n\nHepatic:\n\n* Bilirubin no greater than 1.25 times upper limit of normal (ULN)\n* Transaminases less than 2.5 times ULN (5 times ULN if liver metastases present)\n\nRenal:\n\n* For patients age 18 to 69:\n\n  * Creatinine no greater than ULN\n* For patients age 70 and over:\n\n  * Creatinine clearance normal\n\nCardiovascular:\n\n* LVEF normal by MUGA or echocardiogram\n* No clinical heart failure\n\nPulmonary:\n\n* No malignancy-associated dyspnea at rest\n* No requirement for supportive oxygen therapy\n\nOther:\n\n* Not pregnant or nursing\n* No other prior or concurrent malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or basal cell skin cancer\n* No psychological, familial, sociological, or geographical condition that would preclude compliance with study therapy and follow-up schedule\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* No prior anti-c-erbB2 antibody, including trastuzumab (Herceptin\u00ae)\n* No other concurrent biologic therapy\n\nChemotherapy:\n\n* No more than 1 prior chemotherapy regimen for metastatic breast cancer\n* Prior combination of cyclophosphamide, methotrexate, and fluorouracil (CMF) allowed in the adjuvant or metastatic setting only if the disease-free interval after completion of CMF was at least 12 months\n* Prior anthracyclines and/or taxanes allowed\n* At least 4 weeks since prior anthracyclines\n* No prior cumulative dose of doxorubicin more than 360 mg/m\\^2\n* No prior cumulative dose of epirubicin more than 720 mg/m\\^2\n* No prior cumulative dose of mitoxantrone more than 90 mg/m\\^2\n* No other concurrent chemotherapy\n\nEndocrine therapy:\n\n* More than 2 weeks since prior hormonal therapy in the adjuvant or metastatic setting\n* No concurrent hormonal therapy\n\nRadiotherapy:\n\n* See Disease Characteristics\n* No concurrent radiotherapy\n\nSurgery:\n\n* Not specified\n\nOther:\n\n* No other concurrent anticancer therapy or investigational drugs\n* No concurrent bisphosphonates started after study enrollment except for hypercalcemia",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}